21 – 40 of 111
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
The European Artificial Intelligence Strategy: Implications and Challenges for Digital Health
(
- Contribution to journal › Article
-
Mark
Lost on the High Seas without a Safe Harbor or a Shield? Navigating Cross-Border Data Transfers in the Pharmaceutical Sector After Schrems II Invalidation of the EU-US Privacy Shield
(
- Contribution to journal › Article
-
Mark
The EU-US Privacy Shield Regime for Cross-Border Transfers of Personal Data under the GDPR: What are the legal challenges and how might these affect cloud-based technologies, big data, and AI in the medical sector?
(
- Contribution to journal › Article
-
Mark
Regulatory responses to medical machine learning
(
- Contribution to journal › Article
-
Mark
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
(
- Contribution to journal › Article
-
Mark
At the Epicentre of COVID-19 - the Tragic Failure of the Global Supply Chain for Medical Supplies
2020) In Frontiers in Public Health(
- Contribution to journal › Article
-
Mark
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways
(
- Contribution to journal › Article
-
Mark
Social, cultural and economic aspects of antimicrobial resistance
(
- Contribution to journal › Article
-
Mark
Preparing for antimicrobial resistance in the wake of the COVID-19 pandemic: The vision and “social science” mission of the INAMRSS network
2020)(
- Other contribution › Web publication
-
Mark
An EU Comparative Analysis of the Regulation of Clinical Trials Supervisory Bodies in the Aftermath of Regulation 536/2014
(
- Contribution to journal › Article
-
Mark
Establishing the First International Genetic Discrimination Observatory
(
- Contribution to journal › Article
- 2019
-
Mark
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
2019) In Drug Development Research(
- Contribution to journal › Debate/Note/Editorial
-
Mark
An Update on Research- & Bolar exemptions in the U.S. and Europe: Unsolved questions and new developments in an increasingly important area of law
(
- Contribution to journal › Article
-
Mark
The Legal Dimensions of Big Data, Artificial Intelligence and Machine Learning in Pharmaceutical Innovation (original title in accepted version): Editorial to special issue of the European Pharmaceutical Law Review on "Big Data, AI & Machine Learning in Pharmaceutial Innovation"
(
- Contribution to journal › Article
-
Mark
The problem with antibiotics
(
- Contribution to journal › Article
-
Mark
Is Data Sharing Caring Enough About Patient Privacy?: Part I: The Background
2019)(
- Other contribution › Miscellaneous
-
Mark
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2)
2019)(
- Other contribution › Miscellaneous
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)
2019)(
- Other contribution › Miscellaneous
-
Mark
Global Genes, Local Concerns: Legal, Ethical and Scientific Challenges in International Biobanking
2019)(
- Book/Report › Book